Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Characterization of SGN-CD123A, A Potent CD123-Directed Antibody-Drug Conjugate for Acute Myeloid Leukemia.

Li F, Sutherland MK, Yu C, Walter RB, Westendorf L, Valliere-Douglass J, Pan L, Cronkite A, Sussman D, Klussman K, Ulrich M, Anderson ME, Stone IJ, Zeng W, Jonas M, Lewis TS, Goswami M, Wang SA, Senter PD, Law CL, Feldman EJ, Benjamin DR.

Mol Cancer Ther. 2018 Feb;17(2):554-564. doi: 10.1158/1535-7163.MCT-17-0742. Epub 2017 Nov 15.

2.

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

Kung Sutherland MS, Walter RB, Jeffrey SC, Burke PJ, Yu C, Kostner H, Stone I, Ryan MC, Sussman D, Lyon RP, Zeng W, Harrington KH, Klussman K, Westendorf L, Meyer D, Bernstein ID, Senter PD, Benjamin DR, Drachman JG, McEarchern JA.

Blood. 2013 Aug 22;122(8):1455-63. doi: 10.1182/blood-2013-03-491506. Epub 2013 Jun 14.

PMID:
23770776
3.

Development of orally active inhibitors of protein and cellular fucosylation.

Okeley NM, Alley SC, Anderson ME, Boursalian TE, Burke PJ, Emmerton KM, Jeffrey SC, Klussman K, Law CL, Sussman D, Toki BE, Westendorf L, Zeng W, Zhang X, Benjamin DR, Senter PD.

Proc Natl Acad Sci U S A. 2013 Apr 2;110(14):5404-9. doi: 10.1073/pnas.1222263110. Epub 2013 Mar 14.

4.

Preclinical characterization of SGN-70, a humanized antibody directed against CD70.

McEarchern JA, Smith LM, McDonagh CF, Klussman K, Gordon KA, Morris-Tilden CA, Duniho S, Ryan M, Boursalian TE, Carter PJ, Grewal IS, Law CL.

Clin Cancer Res. 2008 Dec 1;14(23):7763-72. doi: 10.1158/1078-0432.CCR-08-0493.

5.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities.

McEarchern JA, Oflazoglu E, Francisco L, McDonagh CF, Gordon KA, Stone I, Klussman K, Turcott E, van Rooijen N, Carter P, Grewal IS, Wahl AF, Law CL.

Blood. 2007 Feb 1;109(3):1185-92. Epub 2006 Oct 12.

PMID:
17038522
6.

Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40.

Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, Wahl AF, Grewal IS.

Cancer Res. 2005 Sep 15;65(18):8331-8. Erratum in: Cancer Res. 2006 Feb 15;66(4):2495.

7.

Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.

Law CL, Cerveny CG, Gordon KA, Klussman K, Mixan BJ, Chace DF, Meyer DL, Doronina SO, Siegall CB, Francisco JA, Senter PD, Wahl AF.

Clin Cancer Res. 2004 Dec 1;10(23):7842-51. Erratum in: Clin Cancer Res. 2005 May 15;11(10):3969.

8.

Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway.

Klussman K, Mixan BJ, Cerveny CG, Meyer DL, Senter PD, Wahl AF.

Bioconjug Chem. 2004 Jul-Aug;15(4):765-73.

PMID:
15264863
9.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, Rejniak SX, Gordon KA, DeBlanc R, Toki BE, Law CL, Doronina SO, Siegall CB, Senter PD, Wahl AF.

Blood. 2003 Aug 15;102(4):1458-65. Epub 2003 Apr 24.

PMID:
12714494
10.

The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease.

Wahl AF, Klussman K, Thompson JD, Chen JH, Francisco LV, Risdon G, Chace DF, Siegall CB, Francisco JA.

Cancer Res. 2002 Jul 1;62(13):3736-42.

11.

Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy.

Mittler RS, Bailey TS, Klussman K, Trailsmith MD, Hoffmann MK.

J Exp Med. 1999 Nov 15;190(10):1535-40.

12.

4-1BB costimulatory signals preferentially induce CD8+ T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses.

Shuford WW, Klussman K, Tritchler DD, Loo DT, Chalupny J, Siadak AW, Brown TJ, Emswiler J, Raecho H, Larsen CP, Pearson TC, Ledbetter JA, Aruffo A, Mittler RS.

J Exp Med. 1997 Jul 7;186(1):47-55.

13.

Surface expression of CD28 single chain Fv for costimulation by tumor cells.

Winberg G, Grosmaire LS, Klussman K, Hayden MS, Fell HP, Ledbetter JA, Mittler RS.

Immunol Rev. 1996 Oct;153:209-23. Review. No abstract available.

PMID:
9010725
14.

CD45-mediated regulation of extracellular calcium influx in a CD4-transfected human T cell line.

Mittler RS, Schieven GL, Dubois PM, Klussman K, O'Connell MP, Kiener PA, Herndon V.

J Immunol. 1994 Jul 1;153(1):84-96.

PMID:
7515932
15.
16.
18.

Costimulation via vascular cell adhesion molecule-1 induces in T cells increased responsiveness to the CD28 counter-receptor B7.

Damle NK, Klussman K, Leytze G, Ochs HD, Aruffo A, Linsley PS, Ledbetter JA.

Cell Immunol. 1993 Apr 15;148(1):144-56.

PMID:
7684325
19.
20.

Differential regulatory effects of intercellular adhesion molecule-1 on costimulation by the CD28 counter-receptor B7.

Damle NK, Klussman K, Linsley PS, Aruffo A, Ledbetter JA.

J Immunol. 1992 Oct 15;149(8):2541-8.

PMID:
1383317
21.

GMP-140 (P-selectin/CD62) binds to chronically stimulated but not resting CD4+ T lymphocytes and regulates their production of proinflammatory cytokines.

Damle NK, Klussman K, Dietsch MT, Mohagheghpour N, Aruffo A.

Eur J Immunol. 1992 Jul;22(7):1789-93.

PMID:
1378017
22.
24.

Outpatient dacryocystorhinostomy.

Dresner SC, Klussman KG, Meyer DR, Linberg JV.

Ophthalmic Surg. 1991 Apr;22(4):222-4.

PMID:
1772483

Supplemental Content

Loading ...
Support Center